Annual Total Expenses
$594.12 M
-$27.51 M-4.42%
December 31, 2023
Summary
- As of February 12, 2025, SUPN annual total expenses is $594.12 million, with the most recent change of -$27.51 million (-4.42%) on December 31, 2023.
- During the last 3 years, SUPN annual total expenses has risen by +$249.32 million (+72.31%).
- SUPN annual total expenses is now -4.42% below its all-time high of $621.62 million, reached on December 31, 2022.
Performance
SUPN Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Expenses
$135.86 M
-$14.25 M-9.49%
September 30, 2024
Summary
- As of February 12, 2025, SUPN quarterly total expenses is $135.86 million, with the most recent change of -$14.25 million (-9.49%) on September 30, 2024.
- Over the past year, SUPN quarterly total expenses has dropped by -$10.34 million (-7.07%).
- SUPN quarterly total expenses is now -23.84% below its all-time high of $178.39 million, reached on September 30, 2022.
Performance
SUPN Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
SUPN Total Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -4.4% | -7.1% |
| 3 y3 years | +72.3% | -7.1% |
| 5 y5 years | +124.7% | -7.1% |
SUPN Total Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -4.4% | +18.8% | -23.8% | +0.3% |
| 5 y | 5-year | -4.4% | +143.3% | -23.8% | +127.8% |
| alltime | all time | -4.4% | +2452.0% | -23.8% | +1580.2% |
Supernus Pharmaceuticals Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $135.86 M(-9.5%) |
| Jun 2024 | - | $150.11 M(+1.5%) |
| Mar 2024 | - | $147.89 M(+1.8%) |
| Dec 2023 | $594.12 M(-4.4%) | $145.32 M(-0.6%) |
| Sep 2023 | - | $146.20 M(-4.0%) |
| Jun 2023 | - | $152.36 M(+1.4%) |
| Mar 2023 | - | $150.24 M(+11.0%) |
| Dec 2022 | $621.62 M(+24.3%) | $135.40 M(-24.1%) |
| Sep 2022 | - | $178.39 M(+12.9%) |
| Jun 2022 | - | $157.96 M(+5.4%) |
| Mar 2022 | - | $149.87 M(-1.3%) |
| Dec 2021 | $500.28 M(+45.1%) | $151.83 M(+31.1%) |
| Sep 2021 | - | $115.78 M(-0.2%) |
| Jun 2021 | - | $115.97 M(-0.6%) |
| Mar 2021 | - | $116.70 M(+18.0%) |
| Dec 2020 | $344.80 M(+41.2%) | $98.86 M(+0.1%) |
| Sep 2020 | - | $98.80 M(+21.7%) |
| Jun 2020 | - | $81.18 M(+23.1%) |
| Mar 2020 | - | $65.96 M(+10.6%) |
| Dec 2019 | $244.18 M(-7.7%) | $59.63 M(-4.5%) |
| Sep 2019 | - | $62.41 M(+0.5%) |
| Jun 2019 | - | $62.10 M(+3.4%) |
| Mar 2019 | - | $60.05 M(-21.1%) |
| Dec 2018 | $264.45 M(+30.5%) | $76.08 M(+16.1%) |
| Sep 2018 | - | $65.52 M(+2.7%) |
| Jun 2018 | - | $63.82 M(+8.1%) |
| Mar 2018 | - | $59.03 M(+9.1%) |
| Dec 2017 | $202.70 M | $54.09 M(-6.8%) |
| Sep 2017 | - | $58.06 M(+16.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | $49.76 M(+22.0%) |
| Mar 2017 | - | $40.79 M(-11.5%) |
| Dec 2016 | $160.79 M(+27.0%) | $46.08 M(+24.6%) |
| Sep 2016 | - | $36.97 M(-7.5%) |
| Jun 2016 | - | $39.98 M(+5.9%) |
| Mar 2016 | - | $37.76 M(+5.4%) |
| Dec 2015 | $126.62 M(+29.3%) | $35.81 M(+4.5%) |
| Sep 2015 | - | $34.28 M(+7.7%) |
| Jun 2015 | - | $31.83 M(+28.9%) |
| Mar 2015 | - | $24.70 M(-5.4%) |
| Dec 2014 | $97.96 M(+32.5%) | $26.11 M(+11.5%) |
| Sep 2014 | - | $23.42 M(-9.6%) |
| Jun 2014 | - | $25.92 M(+15.2%) |
| Mar 2014 | - | $22.50 M(+3.7%) |
| Dec 2013 | $73.94 M(+69.4%) | $21.69 M(+17.7%) |
| Sep 2013 | - | $18.43 M(+17.0%) |
| Jun 2013 | - | $15.76 M(-12.7%) |
| Mar 2013 | - | $18.05 M(+30.5%) |
| Dec 2012 | $43.65 M(+13.2%) | $13.83 M(+11.7%) |
| Sep 2012 | - | $12.38 M(+32.4%) |
| Jun 2012 | - | $9.35 M(+15.6%) |
| Mar 2012 | - | $8.09 M(-21.4%) |
| Dec 2011 | $38.55 M(-4.2%) | $10.29 M(+3.6%) |
| Sep 2011 | - | $9.93 M(+8.5%) |
| Jun 2011 | - | $9.15 M(-0.6%) |
| Mar 2011 | - | $9.20 M(-14.5%) |
| Dec 2010 | $40.23 M(+18.6%) | $10.76 M(+25.1%) |
| Dec 2009 | $33.91 M(-2.4%) | $8.60 M |
| Dec 2008 | $34.75 M(+49.3%) | - |
| Dec 2007 | $23.28 M | - |
FAQ
- What is Supernus Pharmaceuticals annual total expenses?
- What is the all time high annual total expenses for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual total expenses year-on-year change?
- What is Supernus Pharmaceuticals quarterly total expenses?
- What is the all time high quarterly total expenses for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly total expenses year-on-year change?
What is Supernus Pharmaceuticals annual total expenses?
The current annual total expenses of SUPN is $594.12 M
What is the all time high annual total expenses for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual total expenses is $621.62 M
What is Supernus Pharmaceuticals annual total expenses year-on-year change?
Over the past year, SUPN annual total expenses has changed by -$27.51 M (-4.42%)
What is Supernus Pharmaceuticals quarterly total expenses?
The current quarterly total expenses of SUPN is $135.86 M
What is the all time high quarterly total expenses for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly total expenses is $178.39 M
What is Supernus Pharmaceuticals quarterly total expenses year-on-year change?
Over the past year, SUPN quarterly total expenses has changed by -$10.34 M (-7.07%)